Research map: Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts

Back to the article

Papers in this map

  1. STAR: ultrafast universal RNA-seq aligner · Alexander Yu. Dobin · 2012 · 58150 citations · Cited by this paper
  2. Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease · 2026 · Related
  3. Nonparametric Estimation from Incomplete Observations · Edward L. Kaplan · 1958 · 39516 citations · Cited by this paper
  4. Publication Only · 2026 · Related
  5. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome · Bo Li · 2011 · 24061 citations · Cited by this paper
  6. Polygenic scores in the diagnosis of abnormal complete blood count values · 2026 · Related
  7. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor · Michael Hudecek · 2010 · 268 citations · Cited by this paper
  8. Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS) · 2026 · Related
  9. New developments for antibody-drug conjugate-based therapeutic approaches · Bart ECG de Goeij · 2016 · 259 citations · Cited by this paper
  10. From monoclonal to polyfunctional immunotherapy: Reprogramming CAR‐T‐cell therapy with oncolytic viruses in B‐cell malignancies · 2026 · Related
  11. Cancer therapy with antibodies · Suman Paul · 2024 · 249 citations · Cited by this paper
  12. Adult TWIST2 ‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity · 2026 · Related
  13. Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia · Sivasubramanian Baskar · 2008 · 243 citations · Cited by this paper
  14. Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL · 2026 · Related
  15. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies · Natalia L. M. Liem · 2004 · 242 citations · Cited by this paper
  16. EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies · 2026 · Related
  17. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse · Richard B. Lock · 2002 · 212 citations · Cited by this paper
  18. CAR T‐cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma · 2026 · Related
  19. The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers · Suping Zhang · 2012 · 212 citations · Cited by this paper
  20. High‐risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas · 2026 · Related
  21. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design · Jo Lynne Rokita · 2019 · 184 citations · Cited by this paper
  22. Acute lymphoblastic leukaemia · Luca Pagliaro · 2024 · 184 citations · Cited by this paper
  23. Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia · Vincent T. Bicocca · 2012 · 175 citations · Cited by this paper
  24. Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy · Sima Jeha · 2021 · 166 citations · Cited by this paper
  25. ROR1, an embryonic protein with an emerging role in cancer biology · Nicholas C. Borcherding · 2014 · 164 citations · Cited by this paper
  26. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models · Tiziana Vaisitti · 2021 · 95 citations · Cited by this paper
  27. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies · Amir Hossein Daneshmanesh · 2012 · 85 citations · Cited by this paper
  28. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies · Antoine Deslandes · 2014 · 81 citations · Cited by this paper
  29. Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts · Barbara Szymanska · 2012 · 71 citations · Cited by this paper
  30. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia · Yun Chen · 2019 · 63 citations · Cited by this paper
  31. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data · Baron Rubahamya · 2024 · 62 citations · Cited by this paper
  32. Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies · Hema Dave · 2012 · 54 citations · Cited by this paper
  33. How advanced are we in targeting novel subtypes of ALL? · Charles Grenfell Mullighan · 2019 · 50 citations · Cited by this paper
  34. Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies · Carla A. Jaeger-Ruckstuhl · 2024 · 48 citations · Cited by this paper
  35. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia · Mahdi Shabani · 2008 · 47 citations · Cited by this paper
  36. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma · Changying Jiang · 2021 · 45 citations · Cited by this paper
  37. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism · Md Kamrul Hasan · 2020 · 40 citations · Cited by this paper
  38. Therapeutic advances in the targeting of ROR1 in hematological cancers · Adrian-Bogdan Tigu · 2024 · 36 citations · Cited by this paper
  39. Recommendations for the development and validation of flow cytometry‐based receptor occupancy assays · Cherie L. Green · 2015 · 30 citations · Cited by this paper

Source: OpenAlex (CC0)